Frost & Sullivan Awards Genpathway 2008 Healthcare Innovation Award
The award recognizes Genpathway for providing superior services forchromatin immunoprecipitation (ChIP) and DNA methylation assays that directlycontribute to discoveries in gene regulation, epigenetics, and genetranscription.
"Frost & Sullivan recognizes Genpathway for its outstanding efforts toprovide researchers an efficient and economical solution to fast-tracknotoriously difficult ChIP procedures," explained Frost & Sullivan industryanalyst Christianne Bird. "As the recognized experts in ChIP, Genpathwayconsistently is the first to deliver cutting-edge technologies to the marketand teams with top technology providers to offer the newest ChIP techniquesavailable. For its commitment to providing innovative services to advance lifesciences research and drug discovery and its position as the leader in itsfield, Frost & Sullivan is pleased to present Genpathway the 2008 NorthAmerica Services in Drug Discovery Technologies Healthcare Innovation Award."
"Genpathway is honored to be recognized with this prestigious award fromFrost & Sullivan," said Mary Harper, PhD, Chief Scientific Officer ofGenpathway. "As interest in and demand for ChIP and DNA methylation assayscontinues to expand rapidly, our goal is to provide researchers across a broadrange of disease areas and research fields a fast-track to discovery using ourwhole-genome assays. Genpathway's complete ChIP and DNA IP solutions areproving highly valuable for understanding gene regulation and genetic pathwaysby studying transcription factor binding, gene transcription, and epigeneticevents such as DNA methylation and histone modifications."
Frost & Sullivan presents its Annual Award for Innovation in Healthcare tothe company that has introduced truly innovative products, practices, or ideaswithin its industry. The award recognizes the company's innovativecontributions that make it possible to envision a new level of care in thediagnosis, treatment, and management of disease, leading to better outcomesand quality of life for patients; or that lead to improvements in the toolsthat clinicians, diagnosticians, researchers, and healthcare administratorshave at their disposal to improve quality and efficiency in provision ofhealthcare services. The selection of this award is based on interviews andprimary market analysis conducted by Frost & Sullivan's industry analyst team.
About Genpathway (www.genpathway.com)
Genpathway is a pharmacogenomics company that provides specialized drugdiscovery, research, and development services and develops novel diagnosticbiomarkers that predict drug responses, enabling personalized treatments. Thecompany applies its proprietary chromatin and methylated DNAimmunoprecipitation (ChIP) technology to understand gene regulation andgenetic pathways by studying transcription factor binding, gene transcription,and epigenetic events such as DNA methylation and histone modifications. Basedon the information gained from its technology, Genpathway is developing andcommercializing a broad portfolio of clinically validated molecular diagnosticproducts and services that will enable the accurate selection of specificdrugs to efficaciously treat individuals with cancer, immune disorders, andother serious diseases.
About Frost & Sullivan (www.frost.com)
Frost & Sullivan, the Growth Partnership Company, partners with clients toaccelerate their growth. The company's TEAM Research, Growth Consulting, andGrowth Team Membership(TM) empower clients to create a growth-focused culturethat generates, evaluates, and implements effective growth strategies. Frost &Sullivan employs over 45 years of experience in partnering with Global 1000companies, emerging businesses, and the investment community from more than 30offices on six continents. For more information about Frost & Sullivan'sGrowth Partnership Services, visit http://www.frost.com.Contact: Mary Moynihan M2Friend Biocommunications (802) 951-9600 email@example.com
SOURCE Genpathway, Inc.
You May Also Like